Rigel Pharmaceuticals Inc RIGL
Rigel Pharmaceuticals Inc (Nasdaq: RIGL) is a hematology drug developer. Its lead program, TAVALISSE (fostamatinib) and other marketed products, is in Phase 2 for chronic immune thrombocytopenia (ITP); R/R AML mIDH1; RET+ NSCLC/thyroid cancer; ESR1m breast cancer. Its next catalyst on record is R289: Complete dose-expansion enrollment and select recommended Phase 2 dose (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: R289 — Complete dose-expansion enrollment and select recommended Phase 2 dose (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TAVALISSE (fostamatinib) | chronic ITP | small molecule | Approved |
| REZLIDHIA (olutasidenib) | R/R AML with IDH1 mutation | small molecule | Approved |
| GAVRETO (pralsetinib) | RET fusion-positive NSCLC and thyroid cancer | small molecule | Approved |
| VEPPANU (vepdegestrant) | ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer | small molecule | Approved |
| pralsetinib TAPISTRY | RET fusion-positive solid tumors (label expansion) | small molecule | Phase 2 |
| R289 (IRAK1/4 inhibitor) | lower-risk myelodysplastic syndrome | small molecule | Phase 1 |
Recent results and decisions
- May 1, 2026approval Brazil's ANVISA approved TAVALISSE (partner Knight) for adult chronic ITP with insufficient response to prior treatment (ex-US).
Knight Therapeutics Inc. (Knight) received regulatory approval from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) in May for TAVALISSE for the treatment of adult patients with chronic immune thrombocytopenia (ITP)
Filing - May 1, 2026submitted Partner Kissei submitted a Japanese new drug application for olutasidenib in May 2026, triggering a $4.0M milestone (ex-US).
Rigel's partner Kissei Pharmaceutical Co., Ltd. (Kissei) submitted a new drug application for manufacturing and marketing approval in Japan for olutasidenib in May.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.